Background Finding the optimal duration of anticoagulant treatment following an acute event
of deep vein thrombosis (DVT) is challenging. Residual venous obstruction (RVO) has been …

Introduction: Jurisdictions are increasingly focusing on appropriate use of healthcare
services and interventions as a means to improve health system performance. Our …

BACKGROUND Outpatient versus inpatient treatment of deep vein thrombosis (DVT) is
believed to result in equivalent outcomes with decreased costs. Little is known about the …

Objective Evaluate the cost-effectiveness and difference in length-of-stay when patients in
the ED diagnosed with low-risk pulmonary embolism (PE) are managed with early discharge …

BACKGROUND Acute venous thromboembolism (VTE) is prevalent, expensive, and deadly.
Published data at our institution identified significant VTE care variation based on payer …

BACKGROUND The low-molecular-weight heparins (LMWHs) have been shown to be
effective in the outpatient treatment of deep vein thrombosis (DVT). Data regarding …

Acute venous thromboembolism (VTE) is common, costly, and potentially lethal. Therapeutic
anticoagulation requires timely, closely monitored medical follow-up. If ineffective, clinical …

BACKGROUND:: Years may elapse between the publication of results of rigorous
randomized trials and changes in clinical practice. It is not often that a definitive time interval …

Venous thromboembolism (VTE)—comprising deep venous thrombosis (DVT) and
pulmonary embolism (PE)—continues to place significant clinical and economic burdens on …

OBJECTIVE: To evaluate patient satisfaction, effectiveness, and safety of at-home treatment
of acute deep vein thrombosis (DVT) with subcutaneous enoxaparin dosed at 1.5 mg/kg …